Summit Global Investments
Position in SUPN — Supernus Pharmaceuticals, Inc.
CIK 1697953
BOUNTIFUL, UT
Position in SUPN
as of Jun 30, 2026
· filed Aug 3, 2026
Position Value
$206,318
-$22,978 QoQ
Shares Held
4,436
0.0% QoQ
Ownership
0.008%
of shares outstanding
% of Portfolio
0.03%
of 13F equity value
Holder Rank
#227
of 333 holders
Holding Since
Jun 2022
8 quarters on record
Common Shares in SUPN Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - Specialty & Generic
Healthcare · as of Jun 30, 2026Summit Global Investments holds $8,262,843 across 6 Drug Manufacturers - Specialty & Generic names. SUPN ranks #6 (2.5% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | NBIX |
Neurocrine Biosciences Inc
|
29,424 | $4,959,120 | |
| 2 | TAK |
Takeda Pharmaceutical Co Ltd
|
89,173 | $1,429,443 | |
| 3 | UTHR |
UNITED THERAPEUTICS Corp
|
1,863 | $1,009,429 | |
| 4 | PAHC |
Phibro Animal Health Corp
|
10,958 | $344,081 | |
| 5 | ALKS |
Alkermes plc.
|
6,001 | $314,452 | |
| 6 | SUPN |
Supernus Pharmaceuticals, Inc.
This page
|
4,436 | $206,318 |
All Filings in SUPN
Export CSV
8 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $206,318 | 4,436 | Shares | Sole | 2026-08-03 | |
| 2026-03-31 | $229,296 | 4,436 | Shares | Sole | 2026-05-07 | |
| 2025-12-31 | $207,746 | 4,180 | Shares | Sole | 2026-02-18 | |
| 2025-09-30 | $201,148 | 4,209 | Shares | Sole | 2025-11-03 | |
| 2023-03-31 | $1,232,870 | 34,029 | Shares | Sole | 2023-05-04 | |
| 2022-12-31 | $656,328 | 18,400 | Shares | Sole | 2023-01-31 | |
| 2022-09-30 | $619,455 | 18,300 | Shares | Sole | 2022-11-14 | |
| 2022-06-30 | $1,026,660 | 35,500 | Shares | Sole | 2022-08-23 | |
| No filing history on record for this holder in this stock. | ||||||